A new once-daily oral medication, orforglipron (marketed as Foundayo), has demonstrated superior efficacy in lowering blood sugar and reducing body weight compared to oral semaglutide in patients with type 2 diabetes. According to a study led by Dr. Julio Rosenstock at the University of Texas Southwestern Medical Center and published in The Lancet, the drug achieved significant clinical outcomes without the restrictive fasting requirements associated with existing oral GLP-1 treatments.
How does orforglipron compare to current diabetes treatments?
Orforglipron belongs to the GLP-1 receptor agonist class, the same family as popular injectable weight-loss and diabetes drugs. Unlike oral semaglutide, which requires patients to take the medication on an empty stomach with a small amount of water and wait 30 minutes before eating, orforglipron can be taken at any time of day, according to the clinical trial data. In the ACHIEVE-3 trial, which included approximately 1,700 participants across six countries, orforglipron outperformed oral semaglutide on both glycemic control and weight reduction metrics.
More than one-third of participants on the highest dose of orforglipron achieved near-normal A1C levels, compared to only one in eight patients taking oral semaglutide, as reported in the study findings.
What were the primary outcomes of the ACHIEVE-3 trial?
The trial, overseen by Dr. Rosenstock, tracked A1C levels—a measure of average blood sugar over three months—and total weight loss over one year. Patients on the highest dose of orforglipron saw their A1C drop by approximately 2.2 points, while those on the strongest dose of oral semaglutide saw a reduction of about 1.4 points. Regarding weight management, orforglipron users lost nearly 20 pounds (9 kilograms), whereas the comparator group lost approximately 11 pounds (5 kilograms).
What are the side effects and limitations of this new therapy?
Despite its efficacy, orforglipron is associated with gastrointestinal side effects, including nausea, diarrhea, and vomiting, which are common across the GLP-1 drug class. Data from the trial indicates that nearly one in ten participants discontinued use due to these adverse reactions, a rate roughly double that observed in the oral semaglutide arm of the study. Thomas Seck, M.D., a senior executive at the drug manufacturer, Eli Lilly, stated that the company views the drug as a potential first-line therapy for primary care, though long-term data beyond one year is still pending.
What is the projected timeline for clinical availability?
Eli Lilly intends to file for U.S. regulatory approval for orforglipron as a treatment for type 2 diabetes by the end of June 2026. If authorized, the drug could represent a shift in standard care for newly diagnosed patients. By removing the need for injections and restrictive morning fasting routines, the medication aims to improve treatment adherence in primary care settings, according to the manufacturer’s briefing on the study’s implications.
When discussing new medication options with your healthcare provider, always ask for a comparison of known side-effect profiles and how the administration requirements fit into your specific daily routine.
Frequently Asked Questions
Is orforglipron an injectable medication?
No, orforglipron is an oral tablet taken once daily that does not require the strict fasting or water-intake rules required by other oral GLP-1 medications.
How does orforglipron differ from semaglutide?
In head-to-head clinical trials, orforglipron showed greater efficacy in lowering A1C levels and inducing weight loss than oral semaglutide, though it also had a higher reported rate of treatment discontinuation due to gut-related side effects.
Has this drug already been approved for other uses?
Yes, regulators have previously cleared orforglipron for weight loss in adults with obesity, based on studies showing significant weight reduction over one year.
Are you interested in the latest advancements in metabolic health? Subscribe to our newsletter for updates on clinical trials and new treatment protocols.
